SPY337.39-0.05 -0.02%
DIA279.33-0.71 -0.25%
IXIC11,069.21+56.97 0.52%

9 Meters Biopharma, Inc. Announces Issuance Of Patent For Use Of Larazotide In Acute Lung Injury (ALI) And Acute Respiratory Distress Syndrome (ARDS)

U.S. Pat. No. 10,723,763 issued on July 28, 2020, shows Larazotide reduces endothelial barrier permeability in a dose dependent fashion in both ALI and ARDS RALEIGH, NC / ACCESSWIRE / July 28, 2020 / 9 Meters

Benzinga · -

U.S. Pat. No. 10,723,763 issued on July 28, 2020, shows Larazotide reduces endothelial barrier permeability in a dose dependent fashion in both ALI and ARDS

RALEIGH, NC / ACCESSWIRE / July 28, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the U.S. Patent and Trademark Office ("USPTO") issued U.S. Pat. No. 10,723,763, titled, Use of Tight Junction Antagonists in the Treatment of Acute Lung Injury and Acute Respiratory Distress, relating to its proprietary investigational agent, larazotide.